Invitrogen™ Lipofectamine™ MessengerMAX™ Transfection Reagent 

Description

Lipofectamine MessengerMAX mRNA Transfection Reagent delivers amazing mRNA transfection efficiency, enabling improved application outcomes and more biologically relevant research. That's because our novel lipid-based technology is optimized for efficient mRNA transfection without the nuclear entry step that is required with DNA. When combined with our mMESSAGE mMACHINE T7 mRNA Kit with CleanCap Reagent AG, superior mRNA expression is achievable in a wide range of cell types.

Successfully transfect more predictive cell models with a reagent that provides:

• Rapid protein expression—enables quick translation of mRNA into protein, with no risk of genomic integration, accelerating experimental timelines
• Broad cell type applicability—versatile use in a wide range of cell lines, including neurons and primary cell types
• Minimal cytotoxicity—maintains cell viability and health, ideal for sensitive cells and long-term studies
• High-throughput compatibility—suitable for high-throughput screening, facilitating large-scale mRNA transfection studies
• Higher genome editing—up to 10X higher cleavage using CRISPR-Cas9 mRNA

Enable high transfection efficiency in novel genome editing applications

Lipofectamine MessengerMAX reagent helps increase the likelihood of successful cleavage and recombination through highly efficient Cas9 mRNA transfection, ultimately maximizing the efficiency of genetic modifications and simplifying the downstream processes.

Efficiently transfect difficult-to-transfect cells

Lipofectamine MessengerMAX reagent is designed for efficient mRNA transfection into neurons and a broad spectrum of difficult-to-transfect primary cells. This eliminates the need for electroporation and provides a >2-fold improvement in transfection efficiency compared to other lipid-based reagents.

Leverage advantages of mRNA transfection

mRNA transfection does not require nuclear uptake, leading to faster protein expression than DNA transfection, since mRNA translation occurs in the cytoplasm. Additionally, mRNA poses no risk of genomic integration and maintains high transfection efficiency regardless of the cell cycle stage.

Working in vivo? Try our lipid nanoparticle products Vivofectamine™ VF232 Liver LNP Composition in Ethanol (Cat. No. VF232LVCE) and Vivofectamine™ VF233 IM LNP Composition in Ethanol (Cat. No. VF233IMCE) for mRNA transfection in vivo.